Replimune's TUDRIQEV wins FDA accelerated approval, launch set within 60 daysAug 14Quarterly updateReplimune, Inc.
FDA grants accelerated approval to Replimune's TUDRIQEV plus nivolumab for melanomaAug 6Regulatory decisionnivolumabReplimune, Inc.
FDA advisory committee backs RP1 efficacy data in advanced melanoma, 10-3Jul 30Regulatory milestoneReplimune, Inc.
Replimune's RP1 BLA resubmission accepted by FDA; adcomm expected late JulyJun 29Quarterly updateReplimune, Inc.
Sign inSign in